Grant: Master's Award: Canada Graduate Scholarships
Université de Sherbrooke
$17,500.00
Advancing trial readiness in recessive ataxias: Documenting metrological properties of the SARA
EF 2018-19
Résumé
Providing proper care and offering therapeutic possibilities for patients with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is the end goal. The highest worldwide incidence of ARSACS is in Saguenay-Charlevoix, Quebec, home to our research center the GRIMN. For the past 5 years, the GRIMN has been evaluating over 75 ARSACS patients longitudinally, as well as collecting and analyzing their data, setting up the stage for clinical trials to be initiated. With two potential therapeutic compounds, recently shown to significantly reduce symptoms in knockout mice with ARSACS, ensuring clinical trial readiness is key.
The most common neurological scale used to evaluate ataxia is the Scale for Assessment and Rating of Ataxia (SARA). The SARA has yet to be validated in the ARSACS population, limiting potential outcome measures needed to track patient progress, for upcoming clinical trials. This Master’s project, as a first objective, will document the validity of the SARA using a cross-sectional design with data from 75 patients with ARSACS. The second objective is to detect change of the SARA over a 5-year period, using a longitudinal design of 50 patients with ARSACS in their fifth year of follow-up. Finally, the results of this project will advance clinical trial readiness by documenting the validity of the SARA for the ARSACS population.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
411228
Name
Bourcier Dax
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Advancing trial readiness in recessive ataxias: Documenting metrological properties of the SARA
Programtype2
Studentship Programs
Orgnameinp2
Université de Sherbrooke
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Metrological Properties; Autosomal Recessive Spastic Ataxia Of Charlevoix-Saguenay; Cerebellar Ataxia; Construct Validity; Global Impression Of Change; Motor Impairments; Outcome Measures; Prepare Registry; Scale For The Assessment And Rating Of Ataxia; Trial Readiness
Abstract
Providing proper care and offering therapeutic possibilities for patients with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is the end goal. The highest worldwide incidence of ARSACS is in Saguenay-Charlevoix, Quebec, home to our research center the GRIMN. For the past 5 years, the GRIMN has been evaluating over 75 ARSACS patients longitudinally, as well as collecting and analyzing their data, setting up the stage for clinical trials to be initiated. With two potential therapeutic compounds, recently shown to significantly reduce symptoms in knockout mice with ARSACS, ensuring clinical trial readiness is key.
The most common neurological scale used to evaluate ataxia is the Scale for Assessment and Rating of Ataxia (SARA). The SARA has yet to be validated in the ARSACS population, limiting potential outcome measures needed to track patient progress, for upcoming clinical trials. This Master’s project, as a first objective, will document the validity of the SARA using a cross-sectional design with data from 75 patients with ARSACS. The second objective is to detect change of the SARA over a 5-year period, using a longitudinal design of 50 patients with ARSACS in their fifth year of follow-up. Finally, the results of this project will advance clinical trial readiness by documenting the validity of the SARA for the ARSACS population.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bourcier, Dax
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~